A detailed history of Marvin & Palmer Associates Inc transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Marvin & Palmer Associates Inc holds 6,682 shares of VRTX stock, worth $3.04 Million. This represents 3.28% of its overall portfolio holdings.

Number of Shares
6,682
Previous 6,675 0.1%
Holding current value
$3.04 Million
Previous $2.79 Million 12.22%
% of portfolio
3.28%
Previous 2.79%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$392.81 - $485.53 $2,749 - $3,398
7 Added 0.1%
6,682 $3.13 Million
Q1 2024

May 13, 2024

SELL
$407.69 - $446.08 $160,629 - $175,755
-394 Reduced 5.57%
6,675 $2.79 Million
Q4 2023

Feb 12, 2024

SELL
$343.0 - $410.68 $5.21 Million - $6.23 Million
-15,182 Reduced 68.23%
7,069 $2.88 Million
Q3 2023

Nov 13, 2023

SELL
$338.18 - $362.46 $1.39 Million - $1.49 Million
-4,124 Reduced 15.64%
22,251 $7.74 Million
Q2 2023

Aug 10, 2023

SELL
$314.42 - $351.91 $5.11 Million - $5.72 Million
-16,252 Reduced 38.13%
26,375 $9.28 Million
Q1 2023

May 12, 2023

BUY
$283.23 - $323.1 $983,374 - $1.12 Million
3,472 Added 8.87%
42,627 $13.4 Million
Q3 2022

Nov 14, 2022

SELL
$273.83 - $305.53 $520,550 - $580,812
-1,901 Reduced 4.63%
39,155 $11.3 Million
Q2 2022

Aug 09, 2022

SELL
$234.96 - $292.55 $350,090 - $435,899
-1,490 Reduced 3.5%
41,056 $11.6 Million
Q1 2022

May 11, 2022

BUY
$221.42 - $260.97 $9.42 Million - $11.1 Million
42,546 New
42,546 $11.1 Million
Q4 2020

Feb 12, 2021

SELL
$207.01 - $276.09 $4.76 Million - $6.35 Million
-22,999 Closed
0 $0
Q3 2020

Nov 12, 2020

SELL
$255.65 - $303.1 $651,651 - $772,601
-2,549 Reduced 9.98%
22,999 $6.26 Million
Q2 2020

Aug 13, 2020

BUY
$225.48 - $295.8 $1.02 Million - $1.34 Million
4,544 Added 21.63%
25,548 $7.42 Million
Q1 2020

May 12, 2020

BUY
$199.77 - $247.81 $4.2 Million - $5.21 Million
21,004 New
21,004 $5 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $117B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Marvin & Palmer Associates Inc Portfolio

Follow Marvin & Palmer Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marvin & Palmer Associates Inc, based on Form 13F filings with the SEC.

News

Stay updated on Marvin & Palmer Associates Inc with notifications on news.